Patient safety, a top priority for the company
Improving the biosafety of medicinal products is a priority for LFB, both for plasma-derived medicinal products and those derived from biotechnologies.
LFB is supported by a special scientific board, the ISAC (International Safety & Advisory Committee), which advises the company in this area. The committee’s members are international experts.
Special technology integrated into manufacturing processes
The processes used to manufacture LFB’s medicinal products have the benefit of advanced biosafety techniques. Various purification stages and special filtration stages are integrated into the processes, to improve the biosafety of medicinal products.
In the field of plasma-derived medicinal products, viral elimination and inactivation also form integral stages. The techniques used in plasma fractionation include nanofiltration – a technology for removing any pathogens that might be present on the basis of pore size – which has been used by LFB since 1995.